Evercore ISI's Umer Raffat joins BiotechTV for Analyst Thursdays

Nanobiotix's CEO explains how his company is trying to boost the efficacy of radiation therapy

Microbiome developer Seres had unique considerations when building facilities to work with bacteria

Mizuho's Salim Syed joins BiotechTV for Analyst Thursdays

Trying to sell a diabetes drug (SGLT2 inhibitor) for around $1.50 a pill vs the $20 industry norm

Pioneering Medicines' Paul Biondi on today’s deal with Pfizer

Behind the scenes as Aera Therapeutics builds out the lab of the future

Eleven Therapeutics on trying to help Novo Nordisk find the next GalNAc

Korro Bio CEO on RNA editing and the process behind reverse mergers

Citi's Neena Bitritto-Garg joins BiotechTV for Analyst Thursdays

GRO Biosciences demonstrates how automated technologies enable its scientists to test wide spaces.

Where Vertex Ventures HC is looking for opportunities to deploy a new $200 million fund

Baird's Brian Skorney joins BiotechTV for the inaugural episode of Analyst Thursdays

ICER’s newly-named president elect on drug pricing and ICER’s future

Using a cell therapy as a potential treatment for Parkinson’s with BlueRock's CEO

Agios on today’s phase 2 data for the pyruvate kinase activator mitapivat in sickle cell disease

The future of gene editing with Intellia’s CEO

Flagship’s small molecule play Empress emerges out of stealth mode